Pascal Deschatelets, Chief Scientific Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 138,214 shares at $54.92 ($7.5M) on 2024-04-08, disclosed to the SEC on 2024-04-09.
Scheduled sale ($7.5M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $54.12 | 64,379 | $3.5M | 46.5% |
| 2 | $54.12 | 64,379 | $3.5M | 46.5% |
| 3 | $54.92 | 4,728 | $260K | 3.5% |
| 4 | $54.92 | 4,728 | $260K | 3.5% |
| Total | $54.17 avg | 138,214 | $7.5M | 100% |
| Filing → |
| APLS | SELL | 2026-01-15 | $51K | — | Filing → |
| APLS | SELL | 2025-01-30 | $24K | — | Filing → |
| APLS | SELL | 2025-01-23 | $240K | — | Filing → |